PT - JOURNAL ARTICLE AU - Malin Hultcrantz AU - Joshua Richter AU - Cara Rosenbaum AU - Dhwani Patel AU - Eric Smith AU - Neha Korde AU - Sydney Lu AU - Sham Mailankody AU - Urvi Shah AU - Alexander Lesokhin AU - Hani Hassoun AU - Carlyn Tan AU - Francesco Maura AU - Andriy Derkacs AU - Benjamin Diamond AU - Adriana Rossi AU - Roger N. Pearse AU - Deepu Madduri AU - Ajai Chari AU - David Kaminetsky AU - Marc Braunstein AU - Christian Gordillo AU - Faith Davies AU - Sundar Jagannath AU - Ruben Niesvizky AU - Suzanne Lentzsch AU - Gareth Morgan AU - Ola Landgren TI - COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers AID - 10.1101/2020.06.09.20126516 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.09.20126516 4099 - http://medrxiv.org/content/early/2020/06/11/2020.06.09.20126516.short 4100 - http://medrxiv.org/content/early/2020/06/11/2020.06.09.20126516.full AB - Importance New York City is a global epicenter for the SARS-CoV-2 outbreak with a significant number of individuals infected by the virus. Patients with multiple myeloma have a compromised immune system, due to both the disease and anti-myeloma therapies, and may therefore be particularly susceptible to coronavirus disease 2019 (COVID-19); however, there is limited information to guide clinical management.Objective To assess risk factors and outcomes of COVID-19 in patients with multiple myeloma.Design Case-series.Setting Five large academic centers in New York City.Participants Patients with multiple myeloma and related plasma cell disorders who were diagnosed with COVID-19 between March 10th, 2020 and April 30th, 2020.Exposures Clinical features and risk factors were analyzed in relation to severity of COVID-19.Main Outcomes and Measures Descriptive statistics as well as logistic regression were used to estimate disease severity reflected in hospital admissions, intensive care unit (ICU) admission, need for mechanical ventilation, or death.Results Of 100 multiple myeloma patients (male 58%; median age 68, range 41-91) diagnosed with COVID-19, 74 (74%) were admitted; of these 13 (18%) patients were placed on mechanical ventilation, and 18 patients (24%) expired. None of the studied risk factors were significantly associated (P>0.05) with adverse outcomes (ICU-admission, mechanical ventilation, or death): hypertension (N=56) odds ratio (OR) 2.3 (95% confidence interval [CI] 0.9-5.9); diabetes (N=18) OR 1.1 (95% CI 0.3-3.2); age >65 years (N=63) OR 2.0 (95% CI 0.8-5.3); high dose melphalan with autologous stem cell transplant <12 months (N=7) OR 1.2 (95% CI 0.2-7.4), IgG<650 mg/dL (N=42) OR=1.2 (95% CI 0.4-3.1). In the entire series of 127 patients with plasma cell disorders, hypertension was significantly associated with the combined end-point (OR 3.4, 95% CI 1.5-8.1).Conclusions and Relevance Although multiple myeloma patients have a compromised immune system due to both the disease and therapy; in this largest disease specific cohort to date of patients with multiple myeloma and COVID-19, compared to the general population, we found risk factors for adverse outcome to be shared and mortality rates to be within the higher range of officially reported mortality rates.Competing Interest StatementHultcrantz has received funding from the Multiple Myeloma Research Foundation, the Swedish Research Council, Karolinska Institute Foundations, and the Swedish Blood Cancer Foundation. Landgren has received research funding from: National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Leukemia and Lymphoma Society (LLS), Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; Honoraria/ad boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees (IDMCs) for clinical trials lead by Takeda, Merck, Janssen, and Theradex. The remaining authors declare no relevant conflicts of interest.Clinical TrialNAFunding StatementFunding support for this publication was provided by the Memorial Sloan Kettering Core Grant (P30 CA008748).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Memorial Sloan Kettering Cancer Center IRB #18-143All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease contact the corresponding authors for questions regarding clinical data.